ZEDRA
ZEDRA, the fast-growing international specialist in Active Wealth, Corporate & Global Expansion, and Fund solutions, today announces that the firm is launching a new pensions-focused offering – Pensions & Incentives.
The launch follows several recent acquisitions in the UK pension services space by ZEDRA, including Inside Pensions, a leading independent occupational pension scheme governance support provider PTL, a leading independent Pension Trustee and Governance services provider, both in 2021; and most recently, Caledonian Trustees Limited, a specialist provider of professional independent trustee and secretarial services to corporate pension and funeral plans. As the new offering goes live, PTL Limited has adopted the ZEDRA brand and become ZEDRA Governance Limited.
ZEDRA launches this offering as the UK pension trustee and governance services sector is undergoing significant changes and facing challenges that will require both dedicated effort and investment from long-term owners. As the regulatory system has become increasingly complex over recent years, so has the challenge of running a pension scheme for employers and trustees alike.
The number of pension schemes requiring support is expected to continue to grow for the foreseeable future, due to significantly increased regulatory and compliance burdens, a focus on end game strategies which benefit from professional trustee knowledge and understanding, and a lack of available company or member nominated trustees. With its new Pensions & Incentives offering, ZEDRA is expanding its services to meet these needs.
By entering the pension services industry now, ZEDRA strengthens its 20 years of presence in the employee incentive solutions and pension services space, providing global clients with employee benefits, trustee services, pensions and associated administrative solutions, through a dedicated team in Guernsey. Trustee services have always been at the heart of ZEDRA – the firm was founded in 2016 following the sale by Barclays of its -UK and offshore trust business to a group of private investors, including ZEDRA’s current Executive Chairman, Bart Deconinck.
ZEDRA Pensions & Incentives Services will consist of six offices in London, Reading, Leeds, Birmingham, St Albans and Guernsey and is made up of approximately 80 specialists with plans to further expand the team with acquisitions in the near future in the UK and Europe.
Ivo Hemelraad, ZEDRA Chief Executive Officer , said: “We are delighted to further expand our service offering by boosting our presence in the UK pension space. The journey we started with the acquisition of Interben Trustees Limited in 2019 followed by Inside Pensions, PTL and more recently, Caledonian Trustees, brings us to a market leading position for outsourced pension services in the UK pension space and abroad. Our dedicated teams with unrivalled expertise allow us to offer even greater service to those who are committed to providing the highest quality pension schemes available.”
ENDS
Notes to Editors
For more information, please contact:
Greentarget
Jamie Brownlee / Tom Engleback / Eleonore Basle / Sebastian Merrett
+44 203 963 1893
zedra@greentarget.co.uk
About ZEDRA
Find out more at www.zedra.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005197/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom